EMA Authorised: Cabometyx (cabozantinib (s)-malate) — Ipsen Pharma

View source ↗

Summary

The EMA authorised Cabometyx (cabozantinib (s)-malate) for renal cell carcinoma and hepatocellular carcinoma in the EU, with Ipsen Pharma as the marketing autho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Cabometyx (cabozantinib)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Renal Cell;Carcinomas, Hepatocellular. MAH: Ipsen Pharma. Decision date: 15/01/2026. Accelerated assessment